Please login to the form below

Not currently logged in
Email:
Password:

Otsuka Pharmaceutical

This page shows the latest Otsuka Pharmaceutical news and features for those working in and with pharma, biotech and healthcare.

Otsuka joins forces with IBM for Watson-based digital venture

Otsuka joins forces with IBM for Watson-based digital venture

In a statement Otsuka said: “In psychiatry, patient symptoms and medical history are not usually enumerated and are entered into non-standardised electronic medical charts.  . ... The venture will operate independently of Otsuka's pharmaceutical

Latest news

  • FDA knocks-back Otsuka's digital pill plans FDA knocks-back Otsuka's digital pill plans

    Robert McQuade, executive vice president and chief strategy officer, Otsuka Pharmaceutical Development &Commercialisation, said: “While we are disappointed in the FDA's decision not to approve this digital medicine at this ... time, both Otsuka and

  • Otsuka expands CNS presence with Avanir purchase Otsuka expands CNS presence with Avanir purchase

    Deal for US biotech is valued at $3.5bn. Japan-based Otsuka Pharmaceutical has agreed to buy the California biotech Avanir for $3.5bn, expanding its business in diseases of the ... The acquisition will see Otsuka take control of Avanir's portfolio of

  • Otsuka launches European ADPKD forum Otsuka launches European ADPKD forum

    Aims to lead awareness raising plans for rare genetic condition. Otsuka Pharmaceutical Europe has launched a European forum to help lead awareness of the rare genetic condition autosomal dominant polycystic kidney ... Otsuka's interests in the area

  • Otsuka wins approval for TB drug Deltyba Otsuka wins approval for TB drug Deltyba

    Otsuka Pharmaceutical's Deltyba has become the second medicine approved this year in the EU to treat multidrug resistant (MDR) forms of tuberculosis (TB). ... Otsuka challenged this recommendation, and the CHMP later recommended Deltyba after a

  • Tuberculosis: treatment and prevention Tuberculosis: treatment and prevention

    Otsuka Pharmaceutical is developing delamanid, a nitro-dihydroimidazo-oxazole derivative, for use as an oral anti-TB agent. ... Otsuka expects a decision from the European Commission in early 2014. .

More from news
Approximately 1 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • Tools for the digital world Tools for the digital world

    In May Proteus and Otsuka Pharmaceutical Co resubmitted a New Drug Application for the drug-device combination product of Ablify (aripiprazole) embedded with a Proteus ingestible sensor in a single tablet.

  • Deal Watch February 2016 Deal Watch February 2016

    AstraZeneca, Sanofi and Otsuka divested or out-licensed rights to products in certain territories. ... Otsuka Pharmaceutical/ Medimetriks Pharmaceuticals. OPA-15406, topical PDE-4 inhibitor for the treatment of atopic dermatitis (pII).

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Company acquisition. 9, 500. Avanir Pharmaceuticals / Otsuka Pharmaceutical. Portfolio of CNS products, inc Nuedexta marketed for pseudobulbar affect. ... Research collaboration, options to license. 125. ††Ariad Pharmaceuticals / Otsuka Pharmaceutical

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    265.3. Takeda Pharmaceutical/ Otsuka Pharmaceutical. Co-promotion. TAK-438 (vonoprazan fumarate) for acid-related diseases (NDA filed JP). ... 22. Tracon Pharmaceuticals/ Santen Pharmaceutical Co. Licence. Tracon's anti‐endoglin antibodies, including

  • Case study: Demonstrating the need to treat hyponatraemia

    Published: 18 Jan 2012. Demonstrating the need to treat hyponatraemia. Client:Otsuka Pharmaceutical Europe Ltd. ... Frankie Neal, Marketing Director, Specialty Products, Otsuka Pharmaceutical Europe Ltd.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • NanoValent promotes Mark Lewis to COO NanoValent promotes Mark Lewis to COO

    He has worked at a number of pharmaceutical firms including Amersham International (now GE), Chiron (now Novartis) and Farmitalia (now Pfizer). ... Most recently, Lewis served as managing director for Europe at SuperGen (now Otsuka Pharmaceutical)

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics